A Phase II, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682 + MK-8408 in Subjects With Chronic HCV Genotype 1, 2, 3, 4, 5 or 6 Infection
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Aug 2017
At a glance
- Drugs Ruzasvir (Primary) ; Uprifosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 22 Aug 2017 Planned End Date changed from 20 Oct 2017 to 7 Apr 2020.
- 29 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 16 Jan 2017 Planned End Date changed from 1 Sep 2017 to 1 Oct 2017.